{"id":40997,"date":"2025-09-09T14:41:40","date_gmt":"2025-09-09T06:41:40","guid":{"rendered":"https:\/\/flcube.com\/?p=40997"},"modified":"2025-09-09T14:47:04","modified_gmt":"2025-09-09T06:47:04","slug":"sihuan-pharma-secures-ind-for-dual%e2%80%91target-glp%e2%80%911-gcgr-drug-p052-injection","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40997","title":{"rendered":"Sihuan Pharma Secures IND for Dual\u2011Target GLP\u20111\/GCGR Drug P052 Injection"},"content":{"rendered":"\n<p>China\u2011based <strong>Sihuan Pharmaceutical Holdings Group Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/0460:HKG\">HKG: 0460<\/a>)<\/strong> announced that the <strong>Investigational New Drug (IND)<\/strong> for <strong>P052 injection<\/strong>, a novel <strong>Glucagon\u2011Like Peptide\u20111 (GLP\u20111)\/Glucagon Receptor (GCGR) dual\u2011target agonist<\/strong> developed by its subsidiary <strong>Huisheng Biopharmaceutical Co., Ltd.<\/strong>, has received approval from the <strong>National Medical Products Administration (NMPA)<\/strong> for the treatment of type\u202f2 diabetes, overweight and obesity.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-how-p052-works\">How P052 Works<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>GLP\u20111 Activation<\/strong> \u2013 Stimulates GLP\u20111 receptors to boost insulin secretion, lower blood glucose, and induce weight loss.<\/li>\n\n\n\n<li><strong>GCGR Stimulation<\/strong> \u2013 Increases energy expenditure and enhances weight\u2011loss efficacy while improving hepatic fat metabolism.<\/li>\n\n\n\n<li><strong>Dual\u2011Mechanism Advantage<\/strong> \u2013 Combines the glycaemic control of GLP\u20111 agonists with the metabolic benefits of GCGR activation.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pre-clinical-performance\">Pre\u2011Clinical Performance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>P052<\/th><th>Semaglutide (GLP\u20111\u202fonly)<\/th><\/tr><\/thead><tbody><tr><td>Hypoglycaemic effect<\/td><td>Comparable<\/td><td>Comparable<\/td><\/tr><tr><td>Weight\u2011loss effect<\/td><td>Significantly superior<\/td><td>Baseline<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>Pre\u2011clinical studies show that P052 delivers a hypoglycaemic profile on par with the leading GLP\u20111 therapy <strong>semaglutide<\/strong>, while achieving markedly greater weight loss and improved liver fat metabolism.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011Mover Edge<\/strong> \u2013 P052 represents the first dual\u2011target GLP\u20111\/GCGR therapeutic approved in China, positioning Sihuan Pharma as a pioneer in next\u2011generation metabolic medicines.<\/li>\n\n\n\n<li><strong>Portfolio Expansion<\/strong> \u2013 The IND paves the way for Phase\u202fI\/II clinical trials, potentially broadening the company\u2019s diabetes and obesity product line.<\/li>\n\n\n\n<li><strong>Investor Interest<\/strong> \u2013 The approval is expected to boost confidence among shareholders and attract further capital for clinical development.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-next-steps\">Next Steps<\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Initiate Phase\u202fI Trials<\/strong> \u2013 Begin safety and dose\u2011finding studies in healthy volunteers and patients with type\u202f2 diabetes.<\/li>\n\n\n\n<li><strong>Biomarker Development<\/strong> \u2013 Validate GLP\u20111 and GCGR engagement markers to guide patient selection.<\/li>\n\n\n\n<li><strong>Global Regulatory Strategy<\/strong> \u2013 Leverage early Chinese approval to support submissions to the FDA and EMA once clinical data mature.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ol>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2025090900074_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025090900074_c.\"><\/object><a id=\"wp-block-file--media-a602cc70-8c95-4176-ba08-8f34a176806d\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2025090900074_c.pdf\">2025090900074_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2025090900074_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-a602cc70-8c95-4176-ba08-8f34a176806d\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China\u2011based Sihuan Pharmaceutical Holdings Group Ltd. (HKG: 0460) announced that the Investigational New Drug (IND)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":41002,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,39,930,3662,86,146],"class_list":["post-40997","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-diabetes","tag-hkg-0460","tag-huisheng-biopharmaceutical","tag-obesity","tag-sihuan-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sihuan Pharma Secures IND for Dual\u2011Target GLP\u20111\/GCGR Drug P052 Injection - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2011based Sihuan Pharmaceutical Holdings Group Ltd. (HKG: 0460) announced that the Investigational New Drug (IND) for P052 injection, a novel Glucagon\u2011Like Peptide\u20111 (GLP\u20111)\/Glucagon Receptor (GCGR) dual\u2011target agonist developed by its subsidiary Huisheng Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration (NMPA) for the treatment of type\u202f2 diabetes, overweight and obesity.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40997\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sihuan Pharma Secures IND for Dual\u2011Target GLP\u20111\/GCGR Drug P052 Injection\" \/>\n<meta property=\"og:description\" content=\"China\u2011based Sihuan Pharmaceutical Holdings Group Ltd. (HKG: 0460) announced that the Investigational New Drug (IND) for P052 injection, a novel Glucagon\u2011Like Peptide\u20111 (GLP\u20111)\/Glucagon Receptor (GCGR) dual\u2011target agonist developed by its subsidiary Huisheng Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration (NMPA) for the treatment of type\u202f2 diabetes, overweight and obesity.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40997\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-09T06:41:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-09T06:47:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0911-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40997#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40997\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sihuan Pharma Secures IND for Dual\u2011Target GLP\u20111\\\/GCGR Drug P052 Injection\",\"datePublished\":\"2025-09-09T06:41:40+00:00\",\"dateModified\":\"2025-09-09T06:47:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40997\"},\"wordCount\":293,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40997#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0911-1.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Diabetes\",\"HKG: 0460\",\"HuiSheng Biopharmaceutical\",\"Obesity\",\"Sihuan Pharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40997#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40997\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40997\",\"name\":\"Sihuan Pharma Secures IND for Dual\u2011Target GLP\u20111\\\/GCGR Drug P052 Injection - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40997#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40997#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0911-1.webp\",\"datePublished\":\"2025-09-09T06:41:40+00:00\",\"dateModified\":\"2025-09-09T06:47:04+00:00\",\"description\":\"China\u2011based Sihuan Pharmaceutical Holdings Group Ltd. (HKG: 0460) announced that the Investigational New Drug (IND) for P052 injection, a novel Glucagon\u2011Like Peptide\u20111 (GLP\u20111)\\\/Glucagon Receptor (GCGR) dual\u2011target agonist developed by its subsidiary Huisheng Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration (NMPA) for the treatment of type\u202f2 diabetes, overweight and obesity.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40997#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40997\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40997#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0911-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0911-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sihuan Pharma Secures IND for Dual\u2011Target GLP\u20111\\\/GCGR Drug P052 Injection\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40997#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sihuan Pharma Secures IND for Dual\u2011Target GLP\u20111\\\/GCGR Drug P052 Injection\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sihuan Pharma Secures IND for Dual\u2011Target GLP\u20111\/GCGR Drug P052 Injection - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2011based Sihuan Pharmaceutical Holdings Group Ltd. (HKG: 0460) announced that the Investigational New Drug (IND) for P052 injection, a novel Glucagon\u2011Like Peptide\u20111 (GLP\u20111)\/Glucagon Receptor (GCGR) dual\u2011target agonist developed by its subsidiary Huisheng Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration (NMPA) for the treatment of type\u202f2 diabetes, overweight and obesity.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40997","og_locale":"en_US","og_type":"article","og_title":"Sihuan Pharma Secures IND for Dual\u2011Target GLP\u20111\/GCGR Drug P052 Injection","og_description":"China\u2011based Sihuan Pharmaceutical Holdings Group Ltd. (HKG: 0460) announced that the Investigational New Drug (IND) for P052 injection, a novel Glucagon\u2011Like Peptide\u20111 (GLP\u20111)\/Glucagon Receptor (GCGR) dual\u2011target agonist developed by its subsidiary Huisheng Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration (NMPA) for the treatment of type\u202f2 diabetes, overweight and obesity.","og_url":"https:\/\/flcube.com\/?p=40997","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-09T06:41:40+00:00","article_modified_time":"2025-09-09T06:47:04+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0911-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40997#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40997"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sihuan Pharma Secures IND for Dual\u2011Target GLP\u20111\/GCGR Drug P052 Injection","datePublished":"2025-09-09T06:41:40+00:00","dateModified":"2025-09-09T06:47:04+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40997"},"wordCount":293,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40997#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0911-1.webp","keywords":["Clinical trial approval \/ initiation","Diabetes","HKG: 0460","HuiSheng Biopharmaceutical","Obesity","Sihuan Pharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40997#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40997","url":"https:\/\/flcube.com\/?p=40997","name":"Sihuan Pharma Secures IND for Dual\u2011Target GLP\u20111\/GCGR Drug P052 Injection - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40997#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40997#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0911-1.webp","datePublished":"2025-09-09T06:41:40+00:00","dateModified":"2025-09-09T06:47:04+00:00","description":"China\u2011based Sihuan Pharmaceutical Holdings Group Ltd. (HKG: 0460) announced that the Investigational New Drug (IND) for P052 injection, a novel Glucagon\u2011Like Peptide\u20111 (GLP\u20111)\/Glucagon Receptor (GCGR) dual\u2011target agonist developed by its subsidiary Huisheng Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration (NMPA) for the treatment of type\u202f2 diabetes, overweight and obesity.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40997#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40997"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40997#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0911-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0911-1.webp","width":1080,"height":608,"caption":"Sihuan Pharma Secures IND for Dual\u2011Target GLP\u20111\/GCGR Drug P052 Injection"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40997#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sihuan Pharma Secures IND for Dual\u2011Target GLP\u20111\/GCGR Drug P052 Injection"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0911-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40997","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40997"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40997\/revisions"}],"predecessor-version":[{"id":41000,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40997\/revisions\/41000"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/41002"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40997"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40997"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40997"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}